The DOI matches its Crossref record.
Risk of haematopoietic cancer in patients with inflammatory bowel disease
Open accessAbstract
Background and aims: Several chronic inflammatory conditions are associated with an increased risk of lymphoma. Whether this applies to inflammatory bowel disease (IBD) is still unclear but of paramount interest, particularly in the safety evaluation of newer immunosuppressive drugs. Reports also indicate a possible increase in the risk of leukaemia in IBD. We therefore assessed the risk of haematopoietic cancers in a large cohort of patients with IBD. Subjects and methods: We performed a population based cohort study using prospectively recorded data, including 47 679 Swedish patients with Crohn’s disease (CD) or ulcerative colitis (UC) assembled from regional cohorts of IBD from 1955 to 1990 (n = 8028) and from the Inpatient Register of 1964–2000 (n = 45 060), with follow up until 2001. Relative risks were expressed as standardised incidence ratios (SIR). Results: Overall, we observed 264 haematopoietic cancers during follow up, which corresponded to a borderline significant 20% increased risk in both UC and CD. In UC, lymphomas occurred as expected (SIR 1.0, n = 87) but myeloid leukaemia occurred significantly more often than expected (SIR 1.8, n = 32). In CD, there was a borderline significant increased lymphoma risk (SIR 1.3, n = 65), essentially confined to the first years of follow up. Proxy markers of disease activity had little impact on lymphoma risk. Conclusion: On average, patients with IBD have a marginally increased risk of haematopoietic cancer. In UC, this is accounted for by an excess of myeloid leukaemia. In CD, a modest short term increase in the risk of lymphoma of unknown significance cannot be excluded but any long term risk increase seems unlikely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Beaugerie, L., Brousse, N., Bouvier, A. M., Colombel, J. F., Lémann, M., Cosnes, J., Hébuterne, X., Cortot, A., Bouhnik, Y., Gendre, J. P., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61302-7 · Cited by 1,115
Ekström Smedby, K., Vajdic, C. M., Falster, M., Engels, E. A., Martínez-Maza, O., Turner, J., Hjalgrim, H., Vineis, P., Seniori Costantini, A., Bracci, P. M., et al. (2008) · Blood · doi:10.1182/blood-2007-10-119974 · Cited by 624
Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype
Smedby, K. E., Hjalgrim, H., Askling, J., Chang, E. T., Gregersen, H., Porwit-MacDonald, A., Sundström, C., Åkerman, M., Melbye, M., Glimelius, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj004 · Cited by 439
Self-citationEuropean Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Annese, V., Beaugerie, L., Egan, L., Biancone, L., Bolling, C., Brandts, C., Dierickx, D., Dummer, R., Fiorino, G., Gornet, J. M., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv141 · Cited by 428
Metadata
- Authors
- Askling, J., Brandt, L., Lapidus, A., Karlén, P., Björkholm, M., Löfberg, R., & Ekbom, A.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-04-14
- Volume
- 54
- Issue
- 5
- Pages
- 617-622
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2155922890
- Cited by
- 225
- References
- 0
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of haematopoietic cancer in patients with inflammatory bowel disease. https://app.cochat.ai/papers/10.1136/gut.2004.051771
- The paper
- Askling, J., Brandt, L., Lapidus, A., Karlén, P., Björkholm, M., Löfberg, R., & Ekbom, A. (2005). Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. https://doi.org/10.1136/gut.2004.051771
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.